CoCites: A citation-based method for searching scientific literature

Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan.

P N Sidharta, A Treiber, J Dingemanse. Clin Pharmacokinet 2015
Times Cited: 26

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.

Ronald J Oudiz, Nazzareno Galiè, Horst Olschewski, Fernando Torres, Adaani Frost, Hossein A Ghofrani, David B Badesch, Michael D McGoon, Vallerie V McLaughlin, Ellen B Roecker, Brooke C Harrison, Darrin Despain, Christopher Dufton, Lewis J Rubin. J Am Coll Cardiol 2009
Times Cited: 166

List of shared articles

Times cited

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
Michele Correale, Armando Ferraretti, Ilenia Monaco, Davide Grazioli, Matteo Di Biase, Natale Daniele Brunetti. Vasc Health Risk Manag 2018

Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.
Jessica B Badlam, Todd M Bull. Ther Adv Chronic Dis 2017

Update on pulmonary arterial hypertension pharmacotherapy.
Arash Velayati, Marcos G Valerio, Michael Shen, Sohaib Tariq, Gregg M Lanier, Wilbert S Aronow. Postgrad Med 2016

A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Martin Bedan, Daniela Grimm, Markus Wehland, Ulf Simonsen, Manfred Infanger, Marcus Krüger. Basic Clin Pharmacol Toxicol 2018

Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension.
Yeliz Enderle, Andreas D Meid, Jörg Friedrich, Ekkehard Grünig, Heinrike Wilkens, Walter E Haefeli, Jürgen Burhenne. Anal Chem 2015